Agilent Technologies, Inc. to Post Q2 2026 Earnings of $1.49 Per Share, Zacks Research Forecasts (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Agilent Technologies in a research report issued to clients and investors on Wednesday, July 31st. Zacks Research analyst S. Mete now expects that the medical research company will post earnings per share of $1.49 for the quarter, down from their previous forecast of $1.53. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.24 per share.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.03. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter last year, the company earned $1.27 EPS. The business’s revenue was down 8.4% on a year-over-year basis.

Several other equities research analysts have also issued reports on A. Evercore ISI increased their target price on shares of Agilent Technologies from $126.00 to $130.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 2nd. Jefferies Financial Group reiterated a “hold” rating and set a $135.00 target price (down previously from $152.00) on shares of Agilent Technologies in a research report on Monday, June 3rd. Citigroup raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $135.00 to $150.00 in a report on Wednesday, July 10th. Wolfe Research downgraded shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Finally, Barclays cut their target price on shares of Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. One analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $138.06.

Agilent Technologies Stock Up 1.1 %

A stock opened at $136.24 on Monday. Agilent Technologies has a one year low of $96.80 and a one year high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. The firm’s fifty day moving average is $133.00 and its 200 day moving average is $138.02. The firm has a market cap of $39.75 billion, a PE ratio of 32.21, a P/E/G ratio of 4.86 and a beta of 1.05.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Western Pacific Wealth Management LP boosted its position in shares of Agilent Technologies by 18.9% during the first quarter. Western Pacific Wealth Management LP now owns 440 shares of the medical research company’s stock worth $64,000 after buying an additional 70 shares during the period. Ballentine Partners LLC grew its position in Agilent Technologies by 2.5% in the 1st quarter. Ballentine Partners LLC now owns 2,963 shares of the medical research company’s stock valued at $431,000 after acquiring an additional 73 shares in the last quarter. Haverford Trust Co grew its position in Agilent Technologies by 1.7% in the 1st quarter. Haverford Trust Co now owns 4,423 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 74 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in Agilent Technologies by 3.2% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,421 shares of the medical research company’s stock worth $337,000 after purchasing an additional 75 shares during the period. Finally, Carmel Capital Partners LLC lifted its position in shares of Agilent Technologies by 1.2% during the fourth quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock worth $933,000 after purchasing an additional 78 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the sale, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $140.00, for a total value of $274,120.00. Following the sale, the chief executive officer now directly owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,916 shares of company stock valued at $2,527,860. Insiders own 0.33% of the company’s stock.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a yield of 0.69%. Agilent Technologies’s payout ratio is 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.